Drug intelligence / Profile preview

JADE-002

Development stage: Preclinical
Lead developer: Jade Biosciences
Modality: Antibody-Based Therapeutics

Overview

JADE-002 is a preclinical-stage antibody drug candidate developed by Jade Biosciences. It is part of an undisclosed antibody discovery program focused on immune system and autoimmune diseases. While the specific target and mechanism of action for JADE-002 have not been publicly disclosed, it is known to be an antibody modality and was nominated as a development candidate under the name "JADE201." The broader pipeline at Jade Biosciences targets critical unmet needs in autoimmune diseases using optimized antibodies[1][2][3][9].

Other names: PR 041PR041PR-041

Beyond the preview

Go deeper on JADE-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JADE-002.

Explore the full profile